Physician profile
Samuel Ivan
NPI 1902366222
$4,633.02
in general payments reported to CMS, 2019-2025
10 companies · $2,056 in 2025
The $2,056 reported for 2025 was more than what 81% of Urology providers received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $20.13 · 2021: $408 · 2022: $529 · 2023: $822 · 2024: $797 · 2025: $2,056.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,475 · Travel and Lodging: $1,125 · Education: $75.66.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,474.64 |
| Travel and Lodging | $1,125.08 |
| Education | $75.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Coloplast Corp | $2,600.00 | 2023-2025 | Titan |
| Boston Scientific Corporation | $1,259.90 | 2020-2025 | Lithovue, Ams 700, Ams 700 Cxr Rte Kit |
| Urogen Pharma, INC. | $155.26 | 2021-2022 | |
| Medtronic, INC. | $148.80 | 2022 | |
| Olympus America INC. | $126.29 | 2022 | |
| Conmed Corporation | $110.36 | 2021 | |
| Heron Therapeutics, INC. | $77.51 | 2021 | |
| Intuitive Surgical, INC. | $75.66 | 2023 | Da Vinci Surgical System |
| Baudax Bio INC. | $67.98 | 2021 | |
| Masimo Corporation | $11.26 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samuel Ivan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.